Marshall Wace
AVEO

Marshall Wace’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Marshall Wace’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,021
Closed -$62K – 4092
2022
Q1 		$62K Buy
+11,021
New +$45.4K ﹤0.01% 3235
2020
Q2 		– Sell
-29,589
Closed -$107K – 2135
2020
Q1 		$107K Buy
29,589
+182
+0.6% +$903 ﹤0.01% 1304
2019
Q4 		$182K Buy
+29,407
New +$217K ﹤0.01% 1362

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Marshall Wace's AVEO Position: Q2 2022 in Review

Marshall Wace sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2022, closing a stake of 11,021 shares — an estimated $62K sold.

Marshall Wace first reported a position in AVEO in Q4 2019 and held it in 3 quarters. The position peaked at $182K in Q4 2019. 56 funds tracked by Wall St. Rank hold AVEO as of Q2 2022.

  • Marshall Wace reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Marshall Wace sold 11,021 AVEO Pharmaceuticals, Inc. shares in Q2 2022, an estimated $62K.
  • Marshall Wace first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2019 and held it in 3 quarters.
  • Marshall Wace's AVEO Pharmaceuticals, Inc. position peaked at $182K in Q4 2019.
  • 56 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.